Evolving Novel Chemical Entities for Management of Benign Prostatic Hyperplasia#

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|17|7|593-602

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.17, Iss.7, 2017-04, pp. : 593-602

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination Pharmacological Therapies for the Management of Benign Prostatic Hyperplasia

By Cohen Seth A.   Parsons J. Kellogg  

Drugs & Aging, Vol. 29, Iss. 4, 2012-04 ,pp. : 275-284

Adis International

Access to resources Recommend Favorite

Dutasteride: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia

By Djavan Bob   Milani Shirin   Fong Yan Kit  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 2, 2005-02 ,pp. : 311-317

Informa Healthcare

Access to resources Recommend Favorite

NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia

By Shore Neal  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 305-310

Informa Healthcare

Access to resources Recommend Favorite

Current evidence supports the use of combination therapy in the management of benign prostatic hyperplasia

By  

Drugs & Therapy Perspectives, Vol. 28, Iss. 12, 2012-12 ,pp. : 5-8

Adis International

Access to resources Recommend Favorite

Finasteride: An Update of its Use in the Management of Symptomatic Benign Prostatic Hyperplasia

By Wilde M.I.   Goa K.L.  

Drugs, Vol. 57, Iss. 4, 1999-04 ,pp. : 557-581

Adis International

Access to resources Recommend Favorite